Rockwell Medical, Inc. (RMTI)
USD 1.23
(13.89%)
USD 1.23
(13.89%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 8.7 Million USD | 113.49% |
| 2022 | 4.07 Million USD | 268.47% |
| 2021 | -2.42 Million USD | -188.81% |
| 2020 | 2.72 Million USD | -4.01% |
| 2019 | 2.83 Million USD | 279.17% |
| 2018 | -1.58 Million USD | -142.8% |
| 2017 | 3.7 Million USD | -45.18% |
| 2016 | 6.75 Million USD | -24.45% |
| 2015 | 8.93 Million USD | 4.59% |
| 2014 | 8.54 Million USD | 28.32% |
| 2013 | 6.65 Million USD | -0.51% |
| 2012 | 6.69 Million USD | 18.62% |
| 2011 | 5.64 Million USD | -42.77% |
| 2010 | 9.86 Million USD | 25.02% |
| 2009 | 7.88 Million USD | 161.46% |
| 2008 | 3.01 Million USD | -0.44% |
| 2007 | 3.02 Million USD | 8.15% |
| 2006 | 2.8 Million USD | -6.77% |
| 2005 | 3 Million USD | 7.11% |
| 2004 | 2.8 Million USD | 9.77% |
| 2003 | 2.55 Million USD | 75.8% |
| 2002 | 1.45 Million USD | 59.37% |
| 2001 | 912.19 Thousand USD | -32.87% |
| 2000 | 1.35 Million USD | 4.52% |
| 1999 | 1.3 Million USD | 333.33% |
| 1998 | 300 Thousand USD | 250.0% |
| 1997 | -200 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 3.06 Million USD | 6.76% |
| 2024 Q2 | 4.55 Million USD | 48.5% |
| 2023 FY | 8.7 Million USD | 113.49% |
| 2023 Q4 | 2.87 Million USD | 30.34% |
| 2023 Q1 | 2.59 Million USD | 11.07% |
| 2023 Q2 | 1.03 Million USD | -60.25% |
| 2023 Q3 | 2.2 Million USD | 113.17% |
| 2022 Q1 | -786 Thousand USD | 64.77% |
| 2022 Q2 | 1.74 Million USD | 322.01% |
| 2022 Q3 | 777 Thousand USD | -55.47% |
| 2022 Q4 | 2.34 Million USD | 201.16% |
| 2022 FY | 4.07 Million USD | 268.47% |
| 2021 Q1 | 401 Thousand USD | 4.16% |
| 2021 Q3 | -329 Thousand USD | -25.57% |
| 2021 Q4 | -2.23 Million USD | -578.12% |
| 2021 Q2 | -262 Thousand USD | -165.34% |
| 2021 FY | -2.42 Million USD | -188.81% |
| 2020 Q2 | 880.56 Thousand USD | -20.88% |
| 2020 FY | 2.72 Million USD | -4.01% |
| 2020 Q4 | 385 Thousand USD | 11.27% |
| 2020 Q3 | 346 Thousand USD | -60.71% |
| 2020 Q1 | 1.11 Million USD | 0.1% |
| 2019 Q2 | 733.14 Thousand USD | -27.44% |
| 2019 Q1 | 1.01 Million USD | -14.67% |
| 2019 FY | 2.83 Million USD | 279.17% |
| 2019 Q4 | 1.11 Million USD | 6893.97% |
| 2019 Q3 | -16.36 Thousand USD | -102.23% |
| 2018 Q4 | 1.18 Million USD | -39.85% |
| 2018 Q3 | 1.96 Million USD | 149.01% |
| 2018 FY | -1.58 Million USD | -142.8% |
| 2018 Q1 | 29.5 Thousand USD | 102.41% |
| 2018 Q2 | -4.01 Million USD | -13713.75% |
| 2017 FY | 3.7 Million USD | -45.18% |
| 2017 Q4 | -1.22 Million USD | -214.37% |
| 2017 Q3 | 1.07 Million USD | -28.52% |
| 2017 Q2 | 1.49 Million USD | -36.45% |
| 2017 Q1 | 2.35 Million USD | 18.57% |
| 2016 Q1 | 1.69 Million USD | -17.57% |
| 2016 FY | 6.75 Million USD | -24.45% |
| 2016 Q4 | 1.98 Million USD | 25.84% |
| 2016 Q2 | 1.48 Million USD | -12.12% |
| 2016 Q3 | 1.57 Million USD | 6.07% |
| 2015 Q2 | 2.06 Million USD | -10.66% |
| 2015 Q4 | 2.05 Million USD | -17.87% |
| 2015 FY | 8.93 Million USD | 4.59% |
| 2015 Q1 | 2.31 Million USD | -10.25% |
| 2015 Q3 | 2.5 Million USD | 21.17% |
| 2014 Q2 | 2.01 Million USD | 20.18% |
| 2014 Q4 | 2.57 Million USD | 13.51% |
| 2014 Q3 | 2.26 Million USD | 12.43% |
| 2014 Q1 | 1.67 Million USD | -18.44% |
| 2014 FY | 8.54 Million USD | 28.32% |
| 2013 Q1 | 1.28 Million USD | -24.75% |
| 2013 FY | 6.65 Million USD | -0.51% |
| 2013 Q4 | 2.05 Million USD | 26.12% |
| 2013 Q3 | 1.63 Million USD | -3.07% |
| 2013 Q2 | 1.68 Million USD | 31.54% |
| 2012 Q2 | 1.71 Million USD | 5.68% |
| 2012 Q4 | 1.7 Million USD | 3.42% |
| 2012 FY | 6.69 Million USD | 18.62% |
| 2012 Q1 | 1.62 Million USD | 5.33% |
| 2012 Q3 | 1.64 Million USD | -4.24% |
| 2011 FY | 5.64 Million USD | -42.77% |
| 2011 Q4 | 1.54 Million USD | 12.2% |
| 2011 Q3 | 1.37 Million USD | 28.49% |
| 2011 Q2 | 1.07 Million USD | -35.15% |
| 2011 Q1 | 1.65 Million USD | -30.47% |
| 2010 Q3 | 2.4 Million USD | -13.4% |
| 2010 Q1 | 2.31 Million USD | -4.7% |
| 2010 Q2 | 2.77 Million USD | 19.8% |
| 2010 FY | 9.86 Million USD | 25.02% |
| 2010 Q4 | 2.37 Million USD | -1.03% |
| 2009 Q1 | 1.19 Million USD | 312.97% |
| 2009 Q4 | 2.42 Million USD | 0.87% |
| 2009 Q2 | 1.85 Million USD | 55.91% |
| 2009 FY | 7.88 Million USD | 161.46% |
| 2009 Q3 | 2.4 Million USD | 29.4% |
| 2008 FY | 3.01 Million USD | -0.44% |
| 2008 Q1 | 857.3 Thousand USD | -2.09% |
| 2008 Q4 | 288.86 Thousand USD | -62.9% |
| 2008 Q2 | 1.09 Million USD | 27.35% |
| 2008 Q3 | 778.6 Thousand USD | -28.68% |
| 2007 FY | 3.02 Million USD | 8.15% |
| 2007 Q3 | 1.11 Million USD | 0.26% |
| 2007 Q2 | 1.11 Million USD | 1450.4% |
| 2007 Q1 | -82.71 Thousand USD | -108.62% |
| 2007 Q4 | 875.61 Thousand USD | -21.81% |
| 2006 FY | 2.8 Million USD | -6.77% |
| 2006 Q3 | 593.4 Thousand USD | 27.57% |
| 2006 Q1 | 783.3 Thousand USD | 38.59% |
| 2006 Q4 | 959.7 Thousand USD | 61.73% |
| 2006 Q2 | 465.14 Thousand USD | -40.62% |
| 2005 Q2 | 810.44 Thousand USD | 21.07% |
| 2005 Q3 | 959.98 Thousand USD | 18.45% |
| 2005 Q4 | 565.19 Thousand USD | -41.12% |
| 2005 FY | 3 Million USD | 7.11% |
| 2005 Q1 | 669.41 Thousand USD | -5.4% |
| 2004 Q2 | 682.23 Thousand USD | -1.83% |
| 2004 Q4 | 707.6 Thousand USD | -1.82% |
| 2004 FY | 2.8 Million USD | 9.77% |
| 2004 Q1 | 694.96 Thousand USD | -12.71% |
| 2004 Q3 | 720.69 Thousand USD | 5.64% |
| 2003 Q4 | 796.1 Thousand USD | 11.44% |
| 2003 Q2 | 572.4 Thousand USD | 21.07% |
| 2003 Q1 | 472.8 Thousand USD | -15.89% |
| 2003 FY | 2.55 Million USD | 75.8% |
| 2003 Q3 | 714.37 Thousand USD | 24.8% |
| 2002 Q3 | 415.88 Thousand USD | 57.46% |
| 2002 Q4 | 562.1 Thousand USD | 35.16% |
| 2002 Q1 | 211.65 Thousand USD | 3.13% |
| 2002 FY | 1.45 Million USD | 59.37% |
| 2002 Q2 | 264.11 Thousand USD | 24.79% |
| 2001 Q1 | 346.3 Thousand USD | -25.66% |
| 2001 FY | 912.19 Thousand USD | -32.87% |
| 2001 Q4 | 205.22 Thousand USD | 8.98% |
| 2001 Q3 | 188.31 Thousand USD | -27.4% |
| 2001 Q2 | 259.38 Thousand USD | -25.1% |
| 2000 Q3 | 304.96 Thousand USD | 4.31% |
| 2000 Q2 | 292.35 Thousand USD | -1.1% |
| 2000 Q1 | 295.61 Thousand USD | -40.88% |
| 2000 Q4 | 465.85 Thousand USD | 52.75% |
| 2000 FY | 1.35 Million USD | 4.52% |
| 1999 Q1 | 300 Thousand USD | 0.0% |
| 1999 Q4 | 500 Thousand USD | 66.67% |
| 1999 Q3 | 300 Thousand USD | 50.0% |
| 1999 FY | 1.3 Million USD | 333.33% |
| 1999 Q2 | 200 Thousand USD | -33.33% |
| 1998 Q4 | 300 Thousand USD | 200.0% |
| 1998 FY | 300 Thousand USD | 250.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 FY | -200 Thousand USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 97.149% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | 70.745% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 97.331% |
| Cosmos Health Inc. | 4.34 Million USD | -100.112% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 461.135% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 88.088% |
| Cronos Group Inc. | 6.99 Million USD | -24.505% |
| Incannex Healthcare Limited | 12 Thousand USD | -72433.333% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 2972.607% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 79.202% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 1267.401% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -4.375% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -4.375% |
| SCYNEXIS, Inc. | 124.51 Million USD | 93.01% |
| Safety Shot Inc | -74.45 Thousand USD | 11789.969% |
| Theratechnologies Inc. | 62.12 Million USD | 85.99% |
| Alpha Teknova, Inc. | 10.29 Million USD | 15.462% |
| Universe Pharmaceuticals INC | 10.07 Million USD | 13.633% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 98.225% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -83.435% |
| Dynavax Technologies Corporation | 182.11 Million USD | 95.221% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 98.027% |
| Radius Health, Inc. | 307.71 Million USD | 97.171% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -1471.201% |
| Alvotech | -69.42 Million USD | 112.538% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 97.979% |
| SIGA Technologies, Inc. | 122.09 Million USD | 92.871% |
| Shineco, Inc. | 882.16 Thousand USD | -886.66% |
| Silver Spike Investment Corp. | 8.1 Million USD | -7.422% |
| Journey Medical Corporation | 52.52 Million USD | 83.428% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -107.675% |
| Embecta Corp. | 749.9 Million USD | 98.839% |
| Harrow Health, Inc. | 90.55 Million USD | 90.388% |
| Procaps Group, S.A. | 239.56 Million USD | 96.367% |
| Biofrontera Inc. | 16.62 Million USD | 47.651% |
| DURECT Corporation | 6.83 Million USD | -27.419% |
| PainReform Ltd. | -15 Thousand USD | 58126.667% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 98.338% |
| OptiNose, Inc. | 62.35 Million USD | 86.041% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -184.987% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 97.19% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 74.007% |
| ProPhase Labs, Inc. | 16.23 Million USD | 46.401% |
| Phibro Animal Health Corporation | 312.48 Million USD | 97.215% |
| Procaps Group S.A. | 239.56 Million USD | 96.367% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -568.51% |
| Viatris Inc. | 6.43 Billion USD | 99.865% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 84.055% |
| Tilray Brands, Inc. | 223.35 Million USD | 96.103% |
| PetIQ, Inc. | 252.74 Million USD | 96.556% |
| Talphera, Inc. | -4.89 Million USD | 277.814% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.529% |
| Alimera Sciences, Inc. | 61.17 Million USD | 85.771% |
| Assertio Holdings, Inc. | 125.04 Million USD | 93.04% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 127893.276% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | 67.902% |
| Hempacco Co., Inc. | -1.21 Million USD | 815.888% |
| Alvotech | -69.42 Million USD | 112.538% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 98.773% |
| Kamada Ltd. | 52.59 Million USD | 83.45% |
| Currenc Group, Inc. | 17.35 Million USD | 49.851% |
| Indivior PLC | 907 Million USD | 99.04% |
| Evoke Pharma, Inc. | 4.97 Million USD | -74.823% |
| Flora Growth Corp. | 17.73 Million USD | 50.93% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 461.135% |
| Evolus, Inc. | 140.52 Million USD | 93.806% |
| HUTCHMED (China) Limited | 453.55 Million USD | 98.081% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 97.47% |
| Akanda Corp. | 111.44 Thousand USD | -7709.85% |